Biotech | March 23, 2022
GMP certification for Exothera further extends its viral vector manufacturing capacity
The expansion makes Exothera one of the largest viral vector facilities in Europe
The expansion makes Exothera one of the largest viral vector facilities in Europe
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
OmniActive seeks to improve lives by enhancing nutrition and wellness through science and innovation
This has further strengthened its manufacturing presence in the United States of America
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Subscribe To Our Newsletter & Stay Updated
